Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?-Reference-Cited by-同舟云学术

Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?

Published:2011-04 Issue:1 Volume:78 Page:17-23
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Klastersky Jean,Awada Ahmad

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference37 articles.

1. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics;Wingard;Crit Rev Oncol Hematol,2009

2. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy;Herbst;Cochrane Libr,2009

3. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline;Smith;J Clin Oncol,2006

4. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?;Klastersky;Curr Opin Oncol,2009

5. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients;Lyman;Curr Opin Hematol,2002

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilars accessible in the market for the treatment of cancer;Journal of Controlled Release;2021-08

2. Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review;Critical Reviews in Oncology/Hematology;2021-01

3. Application of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for the prevention of neutropenia in triple negative breast cancer patients older than 65 years during adjuvant chemotherapy;Oncology and Translational Medicine;2019-10

4. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma;Journal of Medical Economics;2019-09-03

5. RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia;Future Oncology;2019-06